Sydney Adventist Hospital 02 9487 9111


Sydney Adventist Hospital
« View pages

Clinical Specialties

Breast Cancer Clinical Trials

D-Care

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence

http://clinicaltrials.gov/ct2/show/NCT01077154


IBIS II

An international multi-centre trial of anastrozole vs placebo in postmenopausal women at increased risk of breast cancer and tamoxifen vs anastrozole in postmenopausal women with hormone sensitive DCIS

http://clinicaltrials.gov/ct2/show/record/NCT00072462


Fergi

A phase II, double-blind, placebo controlled, randomized study of GDC-0941 or GDC-0980 with fulvestrant versus fulvestrant in advanced or metastatic breast cancer in patients resistant to aromastase inhibitor therapy

http://clinicaltrials.gov/ct2/show/NCT01437566


Bolero-6 

CRAD001Y2201: Three arm randomised, open label phase 2 study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with oestrogen receptor positive , locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole

http://clinicaltrials.gov/show/NCT01783444


Metric 

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer

http://clinicaltrials.gov/ct2/show/NCT01997333


NALA

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer who have received two or more prior HER2- Directed Regimens in the Metastatic Setting (NALA)

http://clinicaltrials.gov/ct2/show/NCT01808573


MONARCH 3

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting

https://www.clinicaltrials.gov/ct2/show/NCT02246621?term=I3Y-MC-JPBM&rank=1


SOLAR-1  

A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

https://www.clinicaltrials.gov/ct2/show/NCT02437318?term=placebo+controlled+study+of+alpelisib+in+combination+with+fulvestrant+for+men+and+postmenopausal+women+with+hormone+receptor+positive&rank=1


PUMA 6201 - Recruiting

An Open-Label Study to Characterize the Incidence and Severity of Diarrhoea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

https://clinicaltrials.gov/ct2/show/NCT02400476

Back to Top

Sydney Adventist Hospital Clinical Specialties and Services